BEVACIZUMAB EFFECT ON TOPOTECAN PHARMACOKINETICS ...

74. Taylor, S. and J. Folkman, Protamine is an inhibitor of angiogenesis. Nature,
1982. 297(5864): p. 307-12.
75. Crum, R., S. Szabo, and J. Folkman, A new class of steroids inhibits angiogenesis
in the presence of heparin or a heparin fragment. Science, 1985. 230(4732): p.
1375-8.
76. Maeshima, Y., et al., Tumstatin, an endothelial cell-specific inhibitor of protein
synthesis. Science, 2002. 295(5552): p. 140-3.
77. O'Reilly, M.S., et al., Angiostatin: a novel angiogenesis inhibitor that mediates
the suppression of metastases by a Lewis lung carcinoma. Cell, 1994. 79(2): p.
315-28.
78. Frater-Schroder, M., et al., Tumor necrosis factor type alpha, a potent inhibitor of
endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci U S A,
1987. 84(15): p. 5277-81.
79. Abdollahi, A., et al., Endostatin's antiangiogenic signaling network. Mol Cell,
2004. 13(5): p. 649-63.
80. Hurwitz, H., et al., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med, 2004. 350(23): p. 2335-42.
81. McGee, M.C., et al., Improved intratumoral oxygenation through vascular
normalization increases glioma sensitivity to ionizing radiation. Int J Radiat
Oncol Biol Phys, 2010. 76(5): p. 1537-45.
82. Finn, R.S., et al., Targeting vascular endothelial growth factor with the
monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells
growing in an orthotopic mouse model. Liver Int, 2009. 29(2): p. 284-90.
83. Okada, Y., et al., The effect of bevacizumab on tumour growth of malignant
fibrous histiocytoma in an animal model. Anticancer Res, 2010. 30(9): p. 3391-5.
84. Tol, J., et al., Chemotherapy, bevacizumab, and cetuximab in metastatic
colorectal cancer. N Engl J Med, 2009. 360(6): p. 563-72.
85. Amselem, L., et al., Intravitreal bevacizumab (Avastin) for choroidal metastasis
secondary to breast carcinoma: short-term follow-up. Eye (Lond), 2007. 21(4): p.
566-7.
86. de Gramont, A. and E. Van Cutsem, Investigating the potential of bevacizumab in
other indications: metastatic renal cell, non-small cell lung, pancreatic and
breast cancer. Oncology, 2005. 69 (Suppl 3): p. 46-56.
87. Uegami, S., et al., A case of synchronous multiple liver metastasis of sigmoid
colon cancer with a pathological complete response to combination
chemotherapy of 5-FU/LV and bevacizumab. Gan To Kagaku Ryoho, 2011.
38(2): p. 321-4.
88. Nishida, K., et al., A case with liver resection of metastasis from rectal cancer
after bevacizumab treatment. Gan To Kagaku Ryoho, 2010. 37(12): p. 2517-9.
89. Imaizumi, T., et al., Suppressive effect of bevacizumab on peritoneal
dissemination from gastric cancer in a peritoneal metastasis model. Surg Today,
2010. 40(9): p. 851-7.
90. Yang, H., M.J. Jager, and H.E. Grossniklaus, Bevacizumab suppression of
establishment of micrometastases in experimental ocular melanoma. Invest
Ophthalmol Vis Sci, 2010. 51(6): p. 2835-42.
51